Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | KDM1A | O60341 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | THRB | P10828 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.44 |
| ▸ | DRD3 | P35462 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23663163 | 1.00 | RAB9A (0.50) | RAB9AL3MBTL1KDM1AALDH1A1THRB | |
| SCHEMBL29965837 | 0.87 | KDM1A (0.44) | RAB9AL3MBTL1KDM1AHTR4DRD3 | |
| SCHEMBL30611152 | 0.87 | KDM1A (0.44) | RAB9AL3MBTL1KDM1AHTR4DRD3 | |
| SCHEMBL23671266 | 0.87 | KDM1A (0.44) | RAB9AL3MBTL1KDM1AHTR4DRD3 | |
| SCHEMBL23671267 | 0.87 | KDM1A (0.44) | RAB9AL3MBTL1KDM1AHTR4DRD3 | |
| SCHEMBL23663085 | 0.87 | DRD3 (0.40) | RAB9AL3MBTL1KDM1ATHRBHTR4 | |
| SCHEMBL29965263 | 0.87 | DRD3 (0.40) | RAB9AL3MBTL1KDM1ATHRBHTR4 | |
| SCHEMBL6372077 | 0.87 | L3MBTL1 (0.47) | RAB9AL3MBTL1KDM1AALDH1A1THRB | |
| SCHEMBL23663139 | 0.82 | ALDH1A1 (0.54) | RAB9AL3MBTL1ALDH1A1NPC1HTR4 | |
| SCHEMBL29965195 | 0.82 | ALDH1A1 (0.54) | RAB9AL3MBTL1ALDH1A1NPC1HTR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250320197-A1 | THYROID HORMONE RECEPTOR AGONISTS AND USE THEREOF | ECCOGENE INC (US) | 2025-10-16 | — | — | US | disclosed |
| US-12291518-B2 | Thyroid hormone receptor agonists and use thereof | ECCOGENE INC. (US) | 2025-05-06 | — | — | US | disclosed |
| CN-115244037-B | Substituted triazinones as thyroid hormone receptor agonists | 诚益生物(美国)公司 | 2024-10-25 | — | — | CN | disclosed |
| US-11780825-B2 | Thyroid hormone receptor agonists and use thereof | ECCOGENE (SHANGHAI) CO., LTD. (CN) | 2023-10-10 | — | — | US | disclosed |
| EP-4090652-A1 | SUBSTITUTED TRIAZINONES AS THYROID HORMONE RECEPTOR AGONISTS | Eccogene (Shanghai) Co., Ltd. (CN) | 2022-11-23 | — | — | EP | disclosed |
| CN-115244037-A | Substituted triazinones as thyroid hormone receptor agonists | 上海诚益生物科技有限公司 | 2022-10-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11780825-B2 | Thyroid hormone receptor agonists and use thereof | TSHR, THRA, THRB | RAB9A 2328/4885L3MBTL1 4551/4885KDM1A 4165/4885 |
| US-12291518-B2 | Thyroid hormone receptor agonists and use thereof | TSHR, THRA, THRB | RAB9A 2328/4885L3MBTL1 4551/4885KDM1A 4165/4885 |
| US-20250320197-A1 | THYROID HORMONE RECEPTOR AGONISTS AND USE THEREOF | TSHR, THRA, THRB | RAB9A 2328/4885L3MBTL1 4551/4885KDM1A 4165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.